IL128644A0 - Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment of drug-resistant streptococcus pneumonia - Google Patents

Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment of drug-resistant streptococcus pneumonia

Info

Publication number
IL128644A0
IL128644A0 IL12864497A IL12864497A IL128644A0 IL 128644 A0 IL128644 A0 IL 128644A0 IL 12864497 A IL12864497 A IL 12864497A IL 12864497 A IL12864497 A IL 12864497A IL 128644 A0 IL128644 A0 IL 128644A0
Authority
IL
Israel
Prior art keywords
amoxycillin
clavulanate
medicament
drug
manufacture
Prior art date
Application number
IL12864497A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IL128644A0 publication Critical patent/IL128644A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL12864497A 1996-08-24 1997-08-19 Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment of drug-resistant streptococcus pneumonia IL128644A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9617780.3A GB9617780D0 (en) 1996-08-24 1996-08-24 Method of treatment
PCT/GB1997/002235 WO1998007424A1 (en) 1996-08-24 1997-08-19 Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant streptococcus pneumonia

Publications (1)

Publication Number Publication Date
IL128644A0 true IL128644A0 (en) 2000-01-31

Family

ID=10798919

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12864497A IL128644A0 (en) 1996-08-24 1997-08-19 Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment of drug-resistant streptococcus pneumonia

Country Status (20)

Country Link
US (2) US6214359B1 (cs)
EP (1) EP0938312A1 (cs)
JP (1) JP2000516243A (cs)
KR (1) KR20000068329A (cs)
CN (1) CN1233958A (cs)
AR (1) AR008306A1 (cs)
AU (1) AU722657B2 (cs)
BR (1) BR9711642A (cs)
CA (1) CA2264074A1 (cs)
CO (1) CO5021201A1 (cs)
CZ (1) CZ59299A3 (cs)
GB (1) GB9617780D0 (cs)
HU (1) HUP0201440A3 (cs)
IL (1) IL128644A0 (cs)
NO (1) NO990845L (cs)
NZ (1) NZ334345A (cs)
PL (1) PL331764A1 (cs)
TR (1) TR199900413T2 (cs)
WO (1) WO1998007424A1 (cs)
ZA (1) ZA977564B (cs)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
WO2002030392A2 (en) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
JP4698950B2 (ja) * 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
AU2004258953B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2535177A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) * 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004270170B2 (en) 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
CA2572292A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US9034410B2 (en) * 2011-08-22 2015-05-19 Thomas J. Vella Whole green coffee bean products and methods of production and use
WO2013173808A2 (en) * 2012-05-17 2013-11-21 Michael Spector Methods for use of lower dose compositions of amoxicillin and clavulanate potassium and devices for use
WO2013173803A2 (en) * 2012-05-17 2013-11-21 Michael Spector Formulations of amoxicillin and clavulanate potassium and methods for using same
JP7629693B2 (ja) 2020-04-28 2025-02-14 小林製薬株式会社 抗菌剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
US5753434A (en) 1995-02-10 1998-05-19 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for altering sexual behavior
DZ2028A1 (fr) * 1995-05-03 2002-10-23 Smithkline Beecham Plc Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
AR004510A1 (es) * 1995-09-07 1998-12-16 Smithkline Beecham Plc Composiciones que comprenden amoxicilina y clavulanato, procedimientos para su preparacion y el uso de las composiciones para la fabricacion de unmedicamento

Also Published As

Publication number Publication date
PL331764A1 (en) 1999-08-02
US20020114842A1 (en) 2002-08-22
CO5021201A1 (es) 2001-03-27
ZA977564B (en) 1999-02-22
AU4022697A (en) 1998-03-06
GB9617780D0 (en) 1996-10-02
AU722657B2 (en) 2000-08-10
TR199900413T2 (xx) 1999-06-21
CA2264074A1 (en) 1998-02-26
NO990845L (no) 1999-04-19
US6214359B1 (en) 2001-04-10
NO990845D0 (no) 1999-02-23
AR008306A1 (es) 1999-12-29
KR20000068329A (ko) 2000-11-25
CN1233958A (zh) 1999-11-03
EP0938312A1 (en) 1999-09-01
BR9711642A (pt) 2000-10-24
WO1998007424A1 (en) 1998-02-26
HUP0201440A2 (en) 2002-09-28
JP2000516243A (ja) 2000-12-05
HUP0201440A3 (en) 2003-04-28
CZ59299A3 (cs) 1999-08-11
NZ334345A (en) 2000-10-27

Similar Documents

Publication Publication Date Title
IL128644A0 (en) Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment of drug-resistant streptococcus pneumonia
IL131201A (en) Pharmaceutical formulations comprising amoxycillin and clavulanate
HUP9901437A3 (en) Pharmaceutical formulation, containing amoxycillin and clavulanate
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
IL113433A0 (en) Tablet formulations comprising amoxycillin and salts of clavulanic acid
AU4425496A (en) Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
AU3339897A (en) Sulphonamide derivatives and their use in the treatment of cns disorders
AU6897198A (en) Use of chondroitinase in the manufacture of a medicament in the treatment and prevention of mucoid secretions
AU5127098A (en) Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis
AP9701122A0 (en) Composition comprising amoxycillin and clavulanic acid
AU2466695A (en) The use of famotidine and related compounds in the treatment of movement disorders
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
AU5863894A (en) Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
PT946175E (pt) Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais
AU3099997A (en) The use of tcet in the prophylaxis and treatment of allergies
AU5240700A (en) Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
AU3745895A (en) Use of gaba antagonists in the treatment of emesis
AU8015398A (en) Pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of affections of the oral cavity
HUP9802736A3 (en) Use of 1,4-dihydropyridine derivatives for the preparation of medicament for the prevention and therapy of atherosclerotic degradation in the arterial walls
AU4137596A (en) Method for the treatment of periodontal disease and a pharmaceutical composition useful in said method
HK1022626A (en) Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant streptococcus pneumonia
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory
EP0959887A4 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USING THE SAME
AU3691497A (en) A medicine of external use for treating seborrheic baldness with high efficacy and low side effect and preparation thereof
SI0825860T1 (en) Use of a composition comprising amoxycillin and clavulanic acid for the manufacture of a medicament for the treatment of bacterial infections in paediatric patients